Abstract

Several studies reported on the humoral response in subjects having received the BNT162b2 mRNA COVID-19 vaccine. However, data on the kinetics of antibodies 3 months post-vaccination are currently lacking and are important to drive the future vaccination strategy. The CRO-VAX HCP study is an ongoing multicentre, prospective and interventional study designed to assess the antibody response in a population of healthcare professionals who had received two doses of the BNT162b2 mRNA COVID-19 vaccine. Two hundred individuals underwent a blood drawn within 2 days before the first vaccine dose. One-hundred and forty-two persons (71%) were categorized as seronegative at baseline while 58 (29%) were seropositive. Samples were then collected after 14, 28, 42, 56, and 90 days. Antibodies against the SARS-CoV-2 nucleocapsid and the receptor binding domain of the S1 subunit of the spike protein were measured in all individuals at different time points. Using a one-compartment kinetics model, the time to maximum concentration was estimated at 36 ± 3 days after the first dose and the estimated half-life of antibodies was 55 days (95% CI: 37–107 days) in seronegative participants. In seropositive participants, the time to maximum concentration was estimated at 24 ± 4 days and the estimated half-life was 80 days (95% CI: 46–303 days). The antibody response was higher in seropositive compared to seronegative participants. In both seropositive and seronegative subjects, a significant antibody decline was observed at 3 months compared to the peak response. Nevertheless, the humoral response remained robust in all participants.

Details

Title
Antibody titres decline 3-month post-vaccination with BNT162b2
Author
Favresse, Julien 1 ; Bayart, Jean-Louis 2 ; Mullier, François 3   VIAFID ORCID Logo  ; Elsen, Marc 4 ; Eucher, Christine 4 ; Sandrine Van Eeckhoudt 5 ; Roy, Tatiana 2 ; Wieers, Gregoire 6 ; Laurent, Christine 7 ; Jean-Michel Dogné 8 ; Closset, Mélanie 3 ; Douxfils, Jonathan 9   VIAFID ORCID Logo 

 Department of Laboratory Medicine, Clinique St-Luc Bouge, Namur, Belgium; Department of Pharmacy, Namur Research Institute for LIfe Sciences, University of Namur, Namur, Belgium 
 Department of Laboratory Medicine, Clinique St-Pierre, Ottignies, Belgium 
 Department of Laboratory Medicine, Université catholique de Louvain, CHU UCL Namur, Namur, Belgium 
 Department of Laboratory Medicine, Clinique St-Luc Bouge, Namur, Belgium 
 Department of Internal Medicine, Clinique St-Luc Bouge, Namur, Belgium 
 Department of Internal Medicine, Clinique St-Pierre, Ottignies, Belgium 
 Department of Internal Medicine, Université catholique de Louvain, CHU UCL Namur, Namur, Belgium 
 Department of Pharmacy, Namur Research Institute for LIfe Sciences, University of Namur, Namur, Belgium 
 Department of Pharmacy, Namur Research Institute for LIfe Sciences, University of Namur, Namur, Belgium; Qualiblood sa, Namur, Belgium 
Pages
1495-1498
Publication year
2021
Publication date
Dec 2021
Publisher
Taylor & Francis Ltd.
e-ISSN
22221751
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
3190428825
Copyright
© 2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. This work is licensed under the Creative Commons Attribution License http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.